Premium
Ranibizumab for macular telangiectasia type 2: a pilot study
Author(s) -
BARBAZETTO IRENE,
CONNEY M,
KANCNIK J,
YANNUZZI L
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.4313.x
Subject(s) - medicine , macular telangiectasia , ranibizumab , visual acuity , ophthalmology , fluorescein angiography , telangiectasia , adverse effect , surgery , bevacizumab , chemotherapy
Purpose To investigate safety and maculat telangiectasia type 2. Methods 5 patients were followed monthly and received 3 initial doses of ranibizumab with monthly PRN treatment thereafter. All patients were evaluated by clinical examination, visual acuity, leakage on fluorescein angiography and OCT. Results Results: An average of 8 injections (3‐12) over 12 months were given. Mean VA was 0.49 (LogMar) at BSL, 0.41 at wk 1, 0.42 at M1 and 0.45 at M12. Central macular thickness (CMT) measured 390, 265, 350 and 408 µm respectively. Adverse events were limited to surface irritations. Conclusion Conclusion: Short‐term improvements in visual acuity and CMT, as seen after wk 1, were not sustained over 12 months.